STOCK TITAN

Bio-Techne (TECH) director exercises 589 RSUs, uses shares for taxes

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BIO-TECHNE Corp (TECH) director Amy E. Herr reported indirect equity compensation activity relating to her significant other. On 2026-08-15, 589 restricted stock units covering an equal number of common shares were exercised at $0.00 per share, and 213 common shares were delivered or withheld to cover exercise price or tax liability at $72.40 per share. Following these transactions, she holds 2,680 shares of BIO-TECHNE common stock directly and multiple stock option awards, including options over 2,415 shares at $72.05 expiring in 2035 and 3,777 shares at $60.96 expiring in 2035, along with additional indirect option and RSU positions that vest on various future dates.

Positive

  • None.

Negative

  • None.
Insider Herr Amy E.
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Units F7, F8 118 $0.00 $0.00
Exercise Restricted Stock Units F7, F9 160 $0.00 $0.00
Exercise Restricted Stock Units F7, F11 311 $0.00 $0.00
Exercise Common Stock 589 $0.00 $0.00
Exercise Price or Tax Liability Common Stock 213 $72.40 $15K
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F2 -- -- --
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F3 -- -- --
holding Stock Option (Right to Buy) F4 -- -- --
holding Stock Option (Right to Buy) F5 -- -- --
holding Stock Option (Right to Buy) F6 -- -- --
holding Restricted Stock Units F7, F10 -- -- --
holding Stock Option (Right to Buy) F12 -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 858 shares (Indirect, By significant other); Common Stock — 576 shares (Indirect, By significant other); Stock Option (Right to Buy) — 6,192 shares (Direct); Stock Option (Right to Buy) — 14,283 shares (Indirect, By significant other); Common Stock — 2,680 shares (Direct)
Footnotes (12)
  1. F1. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
  2. F2. Fully vested.
  3. F3. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
  4. F4. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
  5. F5. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
  6. F6. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
  7. F7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  8. F8. 118 restricted stock units vest on 8/15/2026.
  9. F9. 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
  10. F10. 38 restricted stock units vest on 2/3/2027 and 39 restricted stock units vest on 2/3/2028.
  11. F11. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
  12. F12. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
RSUs exercised 589 shares Restricted Stock Units converted into common stock on 2026-08-15
Shares delivered/withheld for exercise price or tax liability 213 shares Code F transaction at $72.40 per share on 2026-08-15
Code F transaction price $72.40 per share Common stock used to pay exercise price or tax liability
Direct common stock holding 2,680 shares BIO-TECHNE common stock held directly after reported transactions
Option position 1 2,415 underlying shares at $72.05 Direct stock option, expiration 2035-02-03
Option position 2 3,777 underlying shares at $60.96 Direct stock option, expiration 2035-10-30
Largest indirect option position 4,472 underlying shares at $66.97 Indirect stock option via significant other, expiration 2027-08-05
Indirect RSU holding 77 underlying shares Restricted stock units indirectly held, each for one common share
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with specified exercise price and expiration date"
exercise price financial
"Options list an exercise price such as 72.0500 or 60.9600 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"Options to purchase or restricted stock units vest on specified future dates"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

What insider transactions did BIO-TECHNE (TECH) director Amy E. Herr report on this Form 4?

Amy E. Herr reported exercise of 589 restricted stock units into common shares and the delivery or withholding of 213 common shares at $72.40 per share to cover exercise price or tax obligations, all held indirectly through her significant other, plus updated option and RSU holdings.

How many BIO-TECHNE (TECH) restricted stock units did Amy E. Herr convert to common stock?

She converted 589 restricted stock units, each representing a contingent right to one BIO-TECHNE common share. These RSUs vest on specified future dates, and the conversion increased indirect common stock exposure while being partly offset by 213 shares delivered or withheld for exercise price or tax obligations.

What common shares were used for exercise price or tax obligations in the BIO-TECHNE (TECH) Form 4?

The filing shows 213 common shares of BIO-TECHNE delivered or withheld at $72.40 per share. This code F transaction is described as payment of exercise price or tax liability by delivering or withholding securities from indirectly held shares of her significant other.

What are Amy E. Herr’s direct BIO-TECHNE (TECH) common stock holdings after these transactions?

After the reported activity, Amy E. Herr holds 2,680 shares of BIO-TECHNE common stock directly. In addition, she has several option awards over thousands of shares and indirect holdings through her significant other, but only the 2,680 shares are reported as direct ownership.

What stock options did Amy E. Herr report holding in BIO-TECHNE (TECH)?

She reported multiple stock option awards on BIO-TECHNE common stock, including 2,415 underlying shares at $72.05 expiring in 2035 and 3,777 underlying shares at $60.96 expiring in 2035, plus several indirect option positions with exercise prices from $53.60 to $120.46 and staggered expirations.

How many BIO-TECHNE (TECH) shares are covered by Amy E. Herr’s indirect stock options?

Indirectly through her significant other, she holds stock options over 4,472 shares at $66.97, 2,076 shares at $120.46, 2,104 shares at $94.52, 1,084 shares at $84.61, 1,468 shares at $74.91, and 2,735 shares at $53.60, with expirations between 2027 and 2035.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Herr Amy E.

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock2,680D
Common Stock08/15/2026M589A$0789IBy significant other
Common Stock08/15/2026F213D$72.4576IBy significant other
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$72.05 (1)02/03/2035Common Stock2,4152,415D
Stock Option (Right to Buy)$60.96 (2)10/30/2035Common Stock3,7773,777D
Stock Option (Right to Buy)$66.97 (1)08/05/2027Common Stock4,4724,472IBy significant other
Stock Option (Right to Buy)$120.46 (1)08/06/2028Common Stock2,0762,076IBy significant other
Stock Option (Right to Buy)$94.52 (3)08/15/2029Common Stock2,1042,104IBy significant other
Stock Option (Right to Buy)$84.61 (4)08/15/2030Common Stock1,0841,084IBy significant other
Stock Option (Right to Buy)$74.91 (5)08/15/2034Common Stock1,4681,468IBy significant other
Stock Option (Right to Buy)$72.05 (6)02/03/2035Common Stock344344IBy significant other
Restricted Stock Units(7)08/15/2026M118 (8) (8)Common Stock118$00IBy significant other
Restricted Stock Units(7)08/15/2026M160 (9) (9)Common Stock160$0160IBy significant other
Restricted Stock Units(7) (10) (10)Common Stock7777IBy significant other
Restricted Stock Units(7)08/15/2026M311 (11) (11)Common Stock311$0621IBy significant other
Stock Option (Right to Buy)$53.6 (12)08/15/2035Common Stock2,7352,735IBy significant other
Explanation of Responses:
1. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
2. Fully vested.
3. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
4. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
5. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
6. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
8. 118 restricted stock units vest on 8/15/2026.
9. 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
10. 38 restricted stock units vest on 2/3/2027 and 39 restricted stock units vest on 2/3/2028.
11. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
12. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)